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Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common inherited disorder of mitochondrial
fatty acid b-oxidation in humans. To better understand the pathogenesis of this disease, we developed a mouse model
for MCAD deficiency (MCAD
 / ) by gene targeting in embryonic stem (ES) cells. The MCAD
 /  mice developed an
organic aciduria and fatty liver, and showed profound cold intolerance at 4 8C with prior fasting. The sporadic cardiac
lesions seen in MCAD
 /  mice have not been reported in human MCAD patients. There was significant neonatal
mortality of MCAD
 /  pups demonstrating similarities to patterns of clinical episodes and mortality in MCAD-deficient
patients. The MCAD-deficient mouse reproduced important aspects of human MCAD deficiency and is a valuable model
for further analysis of the roles of fatty acid oxidation and pathogenesis of human diseases involving fatty acid
oxidation.
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Introduction
Mitochondrial b-oxidation of fatty acids provides energy,
especially during fasting conditions. Fatty acid oxidation
occurs in mitochondria and consists of a repeating circuit of
four sequential steps. There are four straight-chain acyl-CoA
dehydrogenases involved in the initial step. Medium-chain
acyl-CoA dehydrogenase (MCAD) (the mouse gene is Acadm,
whereas the protein is MCAD), speciﬁcally, is responsible for
catalyzing the dehydrogenation of medium-chain length (C6–
C12) fatty acid thioesters [1]. Acadm is transcribed in the
nucleus, translated in the cytosol, and translocated into the
mitochondrial matrix [2–4]. Once inside the mitochondrial
matrix, the MCAD monomers are assembled into homo-
tetramers to gain enzymatic activity [4].
MCAD activity is essential for complete fatty acid oxida-
tion. Inherited MCAD deﬁciency exists in humans as an
autosomal recessive disorder. MCAD deﬁciency was ﬁrst
described in 1982—1983 [5–7] and has been described in
numerous patients [1,8–11]. The carrier frequency in the
Caucasian population has been estimated to be between 1 in
50 to 80 with an incidence of clinical disease expected at
around 1 in 15,000 [1,9,12].
MCAD-deﬁcient patients exhibit clinical episodes often
associated with fasting. Patients manifest disease usually
during the ﬁrst two years of life. Symptoms include
hypoketotic hypoglycemia and Reye-like episodes [1]. It is
estimated that approximately 59% of patients presenting
clinically between 15 to 26 mo of age die during their ﬁrst
clinical episode [1].
The pathogenesis of the wide range of metabolic dis-
turbances in MCAD deﬁciency is poorly understood and
certain aspects of patient management are controversial. An
animal model for MCAD deﬁciency is essential to better
understand the pathogenesis of MCAD deﬁciency and to
develop better management regimens for human patients. To
gain further insight into the mechanisms of this disease, we
developed a mouse model of MCAD deﬁciency by gene
targeting in embryonic stem (ES) cells (for reviews [13,14]).
The mutant mice had many relevant features characteristic of
the disease found in human MCAD-deﬁcient patients, along
with some unexpected ﬁndings.
Results
Gene Targeting and Generation of MCAD-Deficient Mice
MCAD insertion vector (MCAD IV2) was designed to
undergo gap repair of the 1.3-kb deleted region upon
homologous recombination in 129P2 (129P2/OlaHsd) ES cells
E14–1. Correct targeting of the MCAD locus resulted in a
duplication of exons 8, 9, and 10 and integration of ﬂanking
plasmid and Neo sequences (Figure 1A). The insertion vector
was designed to duplicate exon 8, 9, and 10 at the MCAD
locus. Translation of the duplicated exon 8 region results in
the formation of premature stop codons resulting in
truncation of the MCAD monomer. Speciﬁcally, the ﬁrst
premature stop codon arises after translation of only seven
amino acids from the duplicated exon 8. The resulting MCAD
monomer is missing the C-terminal domain a-helixes that are
responsible for making intersubunit contacts to generate the
functional MCAD homotetramer.
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conﬁrmed by Southern blot analysis. Southern blot analysis
used an exon 10 probe (probe A), not present in the targeting
vector, hybridized to a 13.2-kb band in addition to the 3.1-kb
endogenous band indicating targeted insertion of the vector
at the Acadm locus (Figure 1B). Correctly targeted ES cell
clones were microinjected into B6 (C57BL/6NTac) blastocysts
to generate chimeric mice. Chimeric mice were backcrossed
to both 129P2 and B6 inbred mice to produce MCAD
þ/  and
eventually MCAD
 /  mice on a B6/129 mixed background.
The studies described here were conducted exclusively on the
B6/129 mixed background compared with littermate controls
or B6/129 control groups maintained by intercrosses as were
the mutants. Perpetuating this mutation as a congenic mutant
line on the 129P2 background proved impractical. The 129P2
mice were poor breeders as wild-types, and when introduced,
the Acadm mutation was nearly lost on this background
because of the high rate of neonatal death. Because of the
molecular structure of the targeted allele, it proved virtually
impossible to distinguish all three potential genotypes. We
could clearly detect the presence or absence of the targeted
allele, however, whether a particular mouse was MCAD
 /  or
MCAD
þ/  could not be determined by Southern blot or PCR
of genomic DNA. Ultimately MCAD
 /  mice were ascertained
by immunoblot analysis of offspring with subsequent perpet-
uation of MCAD
 /  and MCAD
þ/þ mice as separate groups.
RNA Analysis
RT-PCR ampliﬁcation from exon 7 to 11 from total heart
RNA ampliﬁed the expected 600-base pair (bp) fragment in
MCAD
þ/þ and MCAD
þ/  mice, and a 1.5-kb fragment in
MCAD
 /  mice (data not shown). Sequence analysis of the 1.5-
kb fragment revealed that the ampliﬁed fragment consisted
of exon 7 to exon 10 with 280 bp of pGEM plasmid sequence
followed by exons 8–11. Some of the plasmid sequences, along
with the pPGKNEOpA sequence, were deleted from this
spliced mRNA.
Northern blot analysis revealed Acadm was normally ex-
pressed in all tissues analyzed from MCAD
þ/þ mice with the
most robust expression occurring in brown fat, kidney, heart,
skeletal muscle, and liver with minimal expression in the
brain, white fat, and testes (Figure 2). Interestingly, although
RT-PCR ampliﬁed an incorrectly spliced Acadm transcript, no
Acadm transcripts were detected by northern blot analysis
from MCAD
 /  mice. These results strongly suggest that the
mutant RNA is unstable and degraded rapidly or, alterna-
tively, undergoes nonsense mediated RNA decay.
Liver Enzyme Analyses
Immunoblot analyses of liver homogenates with anti-
MCAD antisera demonstrated that the 42 kDa MCAD
monomer was present in MCAD
þ/þ mice, but not in MCAD
 / 
mice (Figure 3). As a control analysis, anti–short-chain acyl-
CoA dehydrogenase (SCAD) antisera revealed no differences
in levels of expression of SCAD protein between MCAD
þ/þand
MCAD
 /  mice (Figure 3).
Enzyme activity was analyzed in mouse liver homogenates
using the electron transport ﬂavoprotein (ETF) reduction
assay with octanoyl-CoA (C8:0) and palmitoyl-CoA (C16:0)a s
substrates. MCAD
 /  mice had a signiﬁcant reduction in
ability to dehydrogenate octanoyl-CoA and a modest reduc-
tion in activity toward palmitoyl-CoA compared to MCAD
þ/þ
mice (Table 1). Speciﬁcally, the dehydrogenation of octanoyl-
CoA and palmitoyl-CoA substrates were reduced by 75% and
by 30%, respectively, in MCAD
 /  mice as compared to
MCAD
þ/þ controls.
Figure 1. Strategy for Disruption of the Mouse Acadm Gene
(A) The MCAD IV2 insertion targeting vector with a deleted 1.3-kb region
encompassing exon 10 and flanking sequences. MCAD IV2 undergoes
gap repair upon homologous recombination at the endogenous Acadm
locus resulting in a duplication of exons 8, 9, and 10 at the disrupted
allele.
(B) Southern blot analysis of EcoRI-digested genomic DNA from ES cells
screened by PCR. Probe A, a DNA fragment consisting of a portion of
exon 10 that is not present in the targeting vector, hybridizes to an
endogenous 3.1-kb fragment and, upon homologous recombination, to
a 13.2-kb fragment. Lane 1 represents a wild-type ES cell line, and Lane 2
and 3 represent targeted ES cell lines.
DOI: 10.1371/journal.pgen.0010023.g001
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Synopsis
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is one of
the most common inherited disorders of metabolism. This defect in
fatty acid oxidation can lead to severe and sometimes fatal disease,
especially in young children because they are unable to tolerate a
fasting episode. Metabolic complications include very low blood
glucose concentrations and generation of toxic by-products. This
disorder can result in sudden infant death. Using a process known as
gene targeting in mouse embryonic stem cells, the authors have
developed a mouse model with the same enzyme deficiency. This
mouse model of MCAD deficiency develops many of the same
disease characteristics found in affected children. The MCAD-
deficient mouse model shows a high rate of newborn loss,
intolerance to cold, and the characteristic biochemical changes in
the blood, tissues, and urine that are very similar to those found in
the human disease counterpart. The MCAD-deficient mouse model
will allow researchers to better understand disease mechanisms so
that new preventive measures or therapies can be developed.
MCAD Gene Disruption in the MouseNeonatal Deaths
Signiﬁcant neonatal mortality was noted in MCAD
 /  pups.
Although equal numbers of pups were born from MCAD
þ/þ
and MCAD
 /  mice, only 41% of MCAD
 /  mice survived to
weaning as compared to 98% of MCAD
þ/þmice (Table 1). The
mechanism of neonatal loss remains undetermined. The
MCAD
 / pups are abandoned more frequently than MCAD
þ/þ
pups for unknown reasons. They are likely more prone to
hypothermia than MCAD
þ/þ. Because of the difﬁculty of
distinguishing the MCAD
 /  mutants from the MCAD
þ/ 
heterozygous pups by molecular analysis due to the insertion
mutation, we could only compare MCAD
þ/þ 3 MCAD
þ/þ
matings with MCAD
 /  3 MCAD
 /  matings. Thus, we were
unable to evaluate the pedigrees from heterozygous matings.
Fasting and Cold Intolerance
In order to examine the stress effects of fasting on MCAD-
deﬁcient mice, they were fasted for 24 h prior to analysis.
MCAD
 /  mice displayed lower serum glucose and elevated
serum free fatty acid levels although neither result was
signiﬁcant, as compared to MCAD
þ/þ mice (Table 1).
To determine the effects of cold stress, mice were fasted for
18 h and placed in 4 8C environment for a 3-h period. The
MCAD
 /  mice were signiﬁcantly compromised within this
short period of cold stress, some severe enough to result in
fatalities. After 1 h of the cold challenge, the average rectal
temperature of MCAD
 / mice (n¼5) was 23.4 8C as compared
with 35 8C for MCAD
þ/þ mice (n ¼ 4). Rectal temperatures
declined to unrecoverable temperatures of 16.7–19.2 8Ci n
three of the ﬁve MCAD
 /  mice. By the end of the 1.5-h mark,
the two surviving MCAD
 / mice averaged 22.7 8C. In contrast,
all four MCAD
þ/þ mice survived the 3-h cold stress, ending
with an average rectal temperature of 33.6 8C.
Organic Acid and Acylcarnitine Analysis
Urine organic acid analysis revealed that MCAD
 /  mice
developed an organic acid proﬁle similar to MCAD-deﬁcient
human patients. Speciﬁcally, when fasted for 18 h, MCAD
 / 
mice developed signiﬁcantly elevated concentrations of
adipic, suberic, and sebacic acids and hexanoylglycine as
compared to MCAD
þ/þ controls, which showed trace to no
detectable amounts of the same organic acids (Table 1).
Adipic acid is not speciﬁc to MCAD deﬁciency. We also
evaluated b-hydroxybutyric and acetoacetic concentrations
and found no signiﬁcant differences between MCAD geno-
types (data not shown).
Comparison of MCAD
þ/þ and MCAD
 /  mice revealed no
signiﬁcant differences in total serum carnitine concentra-
tions between MCAD
þ/þ and MCAD
 /  mice, but MCAD
 / 
mice had a 5- to 6-fold elevation of serum decenoylcarnitine
evident in the acylcarnitine proﬁle (Figure 4A). Bile acylcar-
nitine analysis revealed a similar acylcarnitine pattern as in
serum (Figure 4B). However, the acylcarnitine proﬁles of the
MCAD
 /  mice are different from those of human MCAD-
deﬁcient patients (Figure 4C). Human patients present with
elevated levels of C6,C 8, and C10:1 acylcarnitines, as did the
mutant mice; however, the predominant peak was C8
acylcarnitine in humans, whereas in the mouse it was C10:1
acylcarnitine.
Histopathology
Complete histopathologic examination of one group of
mutant and MCAD
þ/þ control mice after a 24-h fast
demonstrated diffuse microvesicular and macrovesicular
hepatic steatosis in 6–8-wk-old MCAD
 /  mice whereas
Figure 3. Immunoblots of Liver Homogenates from MCAD
þ/þ and MCAD
 /  Mice
These were probed with anti-MCAD antibody or anti-SCAD antibody. Homozygous MCAD
 /  mice had no detectable MCAD protein. MCAD protein is
only detectable under the MCAD protein–spiked (positive control) lane. As a control analysis, liver homogenates probed with anti-SCAD antibody
revealed that SCAD protein was present in both MCAD
þ/þ and MCAD
 /  mice. No MCAD positive-control protein is detected by anti-SCAD antibodies
(MCAD lane). mw, molecular weight standards.
DOI: 10.1371/journal.pgen.0010023.g003
Figure 2. Northern Blot Analysis from MCAD
 / (n¼2) and MCAD
þ/þ(n¼
2) Mice
Acadm message was detected from the heart, liver, brown fat, brain,
kidney, and muscle (and white fat and testes, data not shown) of only
MCAD
þ/þ mice. Most robust expression occurred in brown fat, kidney,
heart, and skeletal muscle. MCAD
 /  mice had no detectable message in
all tissues examined.
DOI: 10.1371/journal.pgen.0010023.g002
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MCAD Gene Disruption in the MouseMCAD
þ/þ mice had no histologic changes (Figure 5A and 5B).
In another group of 4-wk-old MCAD
þ/þ and MCAD
 /  mice
fasted for 24-h, there were minimal to no abnormalities in all
organs evaluated. Only the older MCAD
 /  mice, therefore,
demonstrated hepatic steatosis. In addition, we found
sporadic cardiac lesions in multiple MCAD
 /  mice.
In one example, an MCAD
 /  mouse had diffuse cardiomy-
opathy with chronic active multifocal myocyte degeneration
and necrosis (Figure 5C and 5D). Changes in degenerating
myocytes included swelling, pale staining, and, in portions of
the sarcoplasm, replacement of myoﬁbrils with ﬁnely gran-
ular eosinophilic material. Nuclei of affected myocytes were
large, pale, and vesicular and had prominent nucleoli. In the
most severely affected areas, there was loss of myocytes
accompanied by ﬁbrosis. In the wall of the aorta at the base of
the heart there was multifocal degeneration of the elastic
tissue, accompanied by multifocal collections of globular
translucent yellow-brown pigment interpreted to be ceroid/
lipofuscin. Similar deposits were scattered within adjacent
adipose tissue.
Discussion
Successfully targeting Acadm produced a mouse model for
MCAD deﬁciency with features that mimic the clinical,
biochemical, and pathologic phenotype found in human
patients. MCAD-deﬁcient patients have abnormal plasma and
urine metabolites associated with the medium chain–length
enzyme speciﬁcity. MCAD-deﬁcient patients [15] often dis-
play a characteristic urinary hexanoylglycine peak, as was
seen in MCAD
 /  mice. Acylcarnitine analysis indicated,
however, mouse MCAD is more active toward longer chain
substrates than the human MCAD enzyme. This ﬁnding is
similar to that seen with very long-chain acyl-CoA dehydro-
genase (VLCAD) where mouse VLCAD is most active toward
C16 acyl-substrates as compared to human VLCAD with the
most enzymatic activity toward C14 acyl-substrates [16].
ETF reduction assays of liver homogenates were performed
to characterize the MCAD
 /  mice at the enzymatic level.
MCAD
 /  mice had a signiﬁcantly reduced ability to dehy-
drogenate C8-CoA, as is the case in human patients where
MCAD activity is reduced to near zero with C8-CoA . This was
less so with palmitoyl-CoA (C16:0). Because there was clearly
no MCAD antigen detected in MCAD
 /  mice, the residual
dehydrogenase activity measured with these two substrates
must represent the activity of other chain length–speciﬁc
acyl-CoA dehydrogenases.
A high degree of neonatal mortality in MCAD
 / mice was a
striking observation and appears to be analogous to the
patterns of clinical episodes and mortality in MCAD-deﬁcient
patients. MCAD
 /  mice exhibited signiﬁcant neonatal mor-
tality with approximately 60% of the MCAD
 /  pups dying
prior to weaning at 3 wk of age. Human patients present with
hypoglycemia, hypoketonemia, and nonketotic organic acidu-
ria precipitated by fasting, most frequently during the ﬁrst 24
mo in life [1]. It is likely that neonatal MCAD
 /  pups are
manifesting sensitivity to fasting with decompensation in a
short period of time if maternal milk is not ingested. In
contrast, no mortality was noted in adult MCAD
 /  mice
unless challenged with cold stress and fasting. Under cold
challenge conditions, however, MCAD
 /  mice were unable to
maintain body temperature. Brown fat is predominantly
responsible for thermogenesis and normally expresses high
levels of Acadm mRNA.
The microvesicular and macrovesicular hepatic steatosis
seen in fasted MCAD
 /  mice is consistent with the primary
pathological ﬁnding seen in human MCAD patients with
fasting stress. Sporadic cardiac lesions in MCAD
 /  mice,
however, were an interesting and unexpected ﬁnding. The
diffuse cardiomyopathy with multifocal myocyte degenera-
tion and necrosis observed in MCAD
 /  mice has not been
reported in human MCAD patients, however, cardiac
arrhythmias and dysfunction have been reported in MCAD-
deﬁcient patients [17, 18]. Interestingly, cardiomyopathy has
been observed in VLCAD deﬁciency [19] and other disorders
of long chain fat metabolism such as severe CPT-1 and -2
deﬁciencies [1]. Thus it is tempting to relate the cardiac
problems in the mouse to the apparent broader range of
substrate utilization of mouse MCAD. The inconsistent liver
and cardiac lesions in these mice is analogous with the
signiﬁcant inter- and intrafamilial phenotypic heterogeneity
seen in MCAD deﬁciency in humans [1,20].
In comparisons with our experiences with the other mouse
models for acyl-CoA dehydrogenase deﬁciencies, the overall
phenotype of MCAD
 /  mice is less severe than that found in
LCAD
 /  mice, yet more pronounced than the VLCAD
 /  or
SCAD
 /  mouse models [16,21,22]. All of these mutants are
cold intolerant and display varying degrees of fatty changes in
liver, heart, and kidney. LCAD
 /  mice show more sponta-
neous deaths and gestational losses than the other deﬁcien-
cies [21]. The signiﬁcant neonatal mortality in MCAD
 /  mice
is distinctive from these other mouse models suggesting a
greater degree of sensitivity to fasting intolerance. The
phenotypes of both the VLCAD
 /  and SCAD
 /  mice are
relatively mild if the animals are not cold stressed [16,22]. The
MCAD-deﬁcient mouse offers new insights into the patho-
genesis of mitochondrial b-oxidation deﬁciencies and will
provide a robust tool to better understand the role of fatty
acids in other relevant diseases.
Table 1. Characteristics of MCAD-Deficient Mice
Characteristic Substrate MCAD
þ/þ MCAD
 /  p-Value
ETF reduction
assay, mU/mg
a
Octanoyl-CoA 32.3 6 5.5 7.74 6 0.84 p , 0.001
Palmitoyl-CoA 21.3 6 10.6 13.1 6 0.70 p ¼ 0.12
Average litter
size
b
Pups born 6.38 5.80 p ¼ 0.35
Pups weaned 6.25 2.40 p , 0.01
Serum glucose and
free fatty acid
concentrations
c
Glucose, mg/dl 205 6 65 150 6 65 p ¼ 0.24
Free fatty acids,
mEq/L
0.50 6 0.14 0.92 6 0.35 p ¼ 0.054
Urinary organic
acids, nmol/mmol
creatinine
d
Adipic 48.5 6 46.0 180 6 25.5 p , 0.001
Suberic 4.43 6 4.49 14.8 6 3.28 p ¼ 0.005
Sebacic 0.32 6 0.63 1.55 6 0.770 p ¼ 0.036
Hexanoylglycine
e 1.77 6 0.97 61.4 6 7.62 p , 0.001
Values given are mean 6 SD.
aMCAD
þ/þ n ¼ 5 and MCAD
 /  n ¼ 5.
bMCAD
þ/þ n ¼ 8 litters and MCAD
 /  n ¼ 10 litters.
cMCAD
þ/þ n ¼ 5 and MCAD
 /  n ¼ 6.
dMCAD
þ/þ n ¼ 4 and MCAD
 /  n ¼ 5.
eExpressed as a ratio relative to the internal standard.
DOI: 10.1371/journal.pgen.0010023.t001
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MCAD Gene Disruption in the MouseFigure 4. Acylcarnitine Analyses
(A) Serum acylcarnitine analysis of MCAD
þ/þ (n ¼ 4) and MCAD
 /  mice (n ¼ 4)
There are significant elevations in acylcarnitine species as indicated in MCAD
 / mice. Values shown are mean values 6 standard deviation (SD). Asterisk
indicates p , 0.002 and z indicates p , 0.01.
(B) There are significant elevations in bile acylcarnitines of the same mice shown in (A) as indicated. Values shown are mean values 6 SD. Asterisk
indicates p , 0.001.
(C) Bile acylcarnitine profile of an MCAD
 / mouse compared to a human patient with MCAD deficiency. Internal standards are indicated by an asterisk.
DOI: 10.1371/journal.pgen.0010023.g004
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MCAD Gene Disruption in the MouseMaterials and Methods
Construction of MCAD targeting vector. A neomycin resistance
gene cassette [23] was subcloned into the SalI site of pGEM11Zf(þ).
The plasmid was digested with EcoRI and the overhangs were ﬁlled
with Klenow enzyme. Subsequent ligation of the blunt ends
recircularized the vector and destroyed the EcoRI site within the
polylinker of the pGEMl1Zf(þ) plasmid. Next, an 8-kb Acadm genomic
fragment spanning exons 8, 9, and 10 and ﬂanking intron sequences,
originally obtained from a Lambda FIXII 129Sv mouse genomic
library [24,25], was directionally cloned into the NotI and XhoI sites
of pGEM11Zf(þ). The vector was digested with BamHI and EcoRI to
remove a 1.3-kb BamHI/EcoRI genomic fragment containing exon 10
and ﬂanking intron sequences. The digested vector, without the 1.3-
kb BamHI/EcoRI genomic fragment, was puriﬁed by gel puriﬁcation
and recircularized by ligation using three oligonucleotides: 59-
AATTGTCGACA-39;5 9GATCGTCGACA-39;a n d5 9-TCGATGTC-
GAC-39. The recircularized vector, resulting from the ligation of
the long arm to the short arm of homology, contained a unique SalI
site where the 1.3-kb exon 10 region was deleted.
Generation of MCAD-deﬁcient mice. The Acadm insertion vector
was linearized by SalI digestion, the site of the 1.3-kb genomic
fragment deletion, and electroporated into E14–1 ES cells (a kind gift
from R. Kuhn), derived from 129P2 mice. Correctly targeted Acadm
insertion vector was designed to undergo gap repair of the 1.3-kb
deletion upon double stranded–break repair [26] during homologous
recombination. Southern blot analysis was conducted to conﬁrm
homologous recombination. Genomic DNA from G418 resistant ES
colonies was digested with EcoRI, electrophoresed, blotted, and
probed with an 850-bp probe (probe A) generated by PCR from
Acadm exon 10 to intron 10. This DNA fragment is not present within
Acadm insertion vector and was expected to hybridize to a 13.2-kb
genomic DNA fragment upon homologous recombination. Correctly
targeted ES cell clones were microinjected into B6 blastocysts to
generate chimeric mice. Chimeric mice were subsequently back-
crossed to B6 and 129P2 mice to produce gene-targeted mice
Acadm
tmUab1/þ (MCAD
þ/ ) and eventually Acadm
tmUab1/tm1Uab MCAD
 / 
(B6;129) mice. Mice were negative for mouse pathogens based on
serological assays for ten different viruses, aerobic bacterial cultures
of nasopharynx and cecum, examinations for endo- and ectopar-
asites, and histopathology of all major organs.
RNA analysis. Total RNA was isolated from the heart of 30 day old
MCAD
þ/þ, MCAD
þ/ , and MCAD
 /  mice by standard techniques using
guanidinium thiocyanate method [27]. Reverse transcription was
performed using random oligonucleotides as recommended by the
manufacturer (Clontech, Mountain View, California, United States).
PCR was subsequently performed using oligonucleotides speciﬁc to
exon 7 and exon 11 of Acadm. PCR ampliﬁcations were performed as
described above. PCR fragments were subsequently sequenced after
subcloning into pGEM-T Easy vector (Promega, Madison, Wisconsin,
United States).
In order to determine the extent of Acadm mRNA expressed from
the MCAD
 /  mice, northern blot analysis was performed. Total RNA
wasisolatedfrom heart,liver, brownfat, brain, kidney,skeletal muscle,
whitefat,andtestesof3-mo-oldMCAD
þ/þandMCAD
 / miceusingthe
Ultraspec RNA Isolation Kit (BIOTEX Laboratories, Inc., Houston,
Texas, United States) as per manufacturer’s protocol. Ten lg of total
RNA from each sample was loaded onto a 0.8% agarose-formaldehyde
gel, transferred to nitrocellulose ﬁlter (Hybond N; GE Healthcare
Amersham Biosciences Corp., Piscataway, New Jersey, United States),
and hybridized with
32P-radiolabeled full-length mouse Acadm cDNA
probeusing standard procedures [28]. Hybridizations were performed
under highly stringent conditions (42 8Ci n2 3SSC, 50% formamide,
10% dextran sulfate, 53 Denhardt’s reagent, 1% SDS, and salmon
sperm DNA) for 18 h. The hybridized ﬁlter was washed two times in 43
SSC,0.1%SDSand twotimes in 23SSC;0.1%SDSat 558C for1h. The
ﬁlter was exposed to autoradiographic ﬁlm (Hyperﬁlm MP; GE
Healthcare Amersham Biosciences, Piscataway, New Jersey, United
States). Replicate agarose-formaldehyde gels were stained by ethidium
bromide to verify equal RNA loading.
Immunoblot analysis of MCAD protein. To evaluate the quantity
of MCAD protein in mouse tissue, liver samples from 6–8-wk-old
MCAD
þ/þ (n ¼ 1) and MCAD
 /  (n ¼ 3) mice were immediately frozen
in liquid nitrogen and stored at  80 8C. For analysis, tissue was
Figure 5. Histopathology of MCAD
þ/þ and MCAD
 /  Mice
(A) MCAD
þ/þ mice had no evidence of hepatic steatosis following a 24-h fast. Liver section with Oil-Red O stain.
(B) Hepatosteatosis in MCAD
 /  mouse following a 24-h fast. Oil-Red O stained liver sections revealed severe and diffuse microvesicular and
macrovesicular hepatic steatosis in MCAD
 /  mice.
(C and D) Diffuse cardiomyopathy with chronic active multifocal myocyte degeneration and necrosis in MCAD
 /  mice.
DOI: 10.1371/journal.pgen.0010023.g005
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MCAD Gene Disruption in the Mousehomogenized and lysed in RIPA buffer (13 PBS, 1% Nonidet P-40,
0.5% sodium deoxycholate, and 1% SDS) with 10% glycerol and
Complete Protease Inhibitor, (Roche Diagnostics Corporation,
Indianapolis, Indiana, United States), 1 mM of phenylmethylsulfo-
nylﬂuoride, and 1 mM of sodium orthovanadate. Lysates were
quantiﬁed by Bradford BCA protein assay (Bio-Rad, Hercules,
California, United States). Protein lysates were denatured, separated
in 8% SDS-PAGE, and transferred overnight onto a 0.45 lm
nitrocellulose membrane (Schleicher and Schuell, Keene, New
Hampshire, United States). After blocking with 5% nonfat milk in
phosphate-buffered saline with 0.1% Tween-20, the membrane was
immunoblotted overnight at 4 8C with 1:500 dilution of an anti-
MCAD antibody. Blots were incubated in anti-mouse IgG HRP-
conjugated secondary antibody for 2–4 h at room temperature using
standard procedures and developed by chemiluminiscence (Renais-
sance, NEN Lifesciences Products, Boston, Massachusetts, United
States).
Liver enzyme activity. In order to evaluate MCAD activity in mice,
liver homogenates were prepared from MCAD
þ/þ(n¼5) and MCAD
 / 
mice (n¼5). The sensitive and highly speciﬁc anaerobic ETF reduction
assaywasusedontissueextractswithoctanoyl-CoA(C8)andpalmitoyl-
CoA (C16) as substrate as previously described [29].
Fasting and cold challenge. Eight-wk-old MCAD
þ/þ and MCAD
 / 
mice were fasted for 18 h (cold tolerance experiments) or 24 h (serum
glucose, free fatty acid, organic acid, and carnitine experiments) prior
to analysis. Glucose concentration was measured in 10 ll sera using an
Ektachem DT II system (Johnson and Johnson Clinical Diagnostics,
Rochester, New York, United States). Total non-esteriﬁed fatty acids
(NEFA)weremeasuredbyanenzymatic,colorimetricmethod(‘‘NEFA-
C’’ reagents, Wako Diagnostics, Richmond, Virginia, United States).
The assay was modiﬁed to accommodate a reduced sample size (10 ll)
and use of a microplate reader for measurement of optical density at
550 nm. Urine organic acid analyses were performed using gas
chromatography-mass spectroscopy as previously described [22,30],
except tetracosane (C24; Sigma, St. Louis, Missouri, United States) was
used as the internal standard, and quantitative determinations were
made based on comparison with synthetic calibration standards.
Acylcarnitine analyses in serum and bile were conducted using
electrospray tandem mass spectrometry [31,32].
Histopathology. Twelve mice were examined for gross and his-
tologic abnormalities, including one male and one female MCAD
 / 
mouse 18-mo-old, one male and one female MCAD
þ/þ mouse 6-mo-
old, two male and two female MCAD
 /  mice 4-wk-old, and two male
and two female MCAD
þ/þ mice 4-wk-old. Kidney, spleen, pancreas,
liver, brain, heart, testicles, ovaries, and skeletal muscle were ﬁxed by
immersion in buffered 10% formalin, processed routinely for
parafﬁn sectioning, sectioned at 5 lm, and stained with hematoxylin
and eosin. Frozen liver sections were prepared using standard
methods and sections were stained with Oil-red-O. Slides were
examined without knowledge of genotype or age. Other mice were
examined because of sporadic clinical disease. Those with visible
cardiac enlargement were evaluated for cardiac lesions.
Statistical analyses. Results between groups were tested for
statistical signiﬁcance using Student’s t-test. A p , 0.05 was set as
signiﬁcant.
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